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A B S T R A C T
Background
Digitalis glycosides have been in clinical use for the treatment of heart failure (HF) for longer than 200 years. In recent years, several
trials have been conducted to address concerns about their efficacy and toxicity.
Objectives
To examine the effectiveness of digitalis glycosides in treating HF in patients with normal sinus rhythm. To examine the effects of
digitalis in patients taking diuretics and angiotensin-converting enzyme inhibitors; in patients with varying severity and duration of
disease; in patients with prior exposure to digitalis versus no prior exposure; and in patients with “HF due to systolic dysfunction”
versus “HF with preserved ejection fraction.”
Search methods
Searches on the following databases were updated in May 2013: The Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, and Dissertation Abstracts. Annual meeting abstracts of the American Heart Association, the American College
of Cardiology, and the European Society of Cardiology were searched from 1996 to March 2013. In addition, reference lists provided
by the pharmaceutical industry (GlaxoSmithKline and Covis Pharma) were searched.
Selection criteria
Included were randomized placebo-controlled trials of 20 or more adult participants of either sex with symptomatic HF who were
studied for seven weeks or longer. Excluded were trials in which the prevalence of atrial fibrillation was 2% or greater, or in which any
arrhythmia that might compromise cardiac function or any potentially reversible cause of HF such as acute ischemic heart disease or
myocarditis was present.
Data collection and analysis
Articles selected from the searches described above were evaluated in a joint effort of the review authors. The staff of the Cochrane
Heart Group ran searches on the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE.
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Main results
No new studies were identified in the updated searches. Thirteen studies (7896 participants) are included, and major endpoints of
mortality, hospitalization, and clinical status, based respectively on 8, 4, and 12 of these selected studies, were recorded and analyzed.
The data show no evidence of a difference in mortality between treatment and control groups, whereas digitalis therapy is associated
with lower rates of both hospitalization and clinical deterioration. The largest study, in which most participants were taking angiotensin-
converting enzyme inhibitors, showed a significant rise in “other cardiac” deaths, possibly due to arrhythmias. However collectively,
these findings were based on studies done before beta-blockers, as well as angiotensin receptor blockers and aldosterone antagonists,
became widely used to treat HF.
Authors’ conclusions
The literature indicates that digitalis may have a useful role in the treatment of patients with HF who are in normal sinus rhythm. New
trials are needed to elucidate the importance of the dosage of digitalis and its usefulness in the era of beta-blockers and other agents
shown to be effective in treating HF.
P L A I N L A N G U A G E S U M M A R Y
Digitalis for treatment of heart failure in patients in sinus rhythm
Digitalis is a drug that is extracted from the leaves of the foxglove plant. It contains substances that stimulate heart muscle. The drug
has been used for over two centuries to treat heart failure-a condition caused by inability of the injured heart to pump blood adequately.
Other drugs that may be useful include diuretics, angiotensin-converting enzyme inhibitors, and beta-blockers, but digitalis may also
be beneficial. The review of trials found that digitalis reduces hospitalization and can help to relieve symptoms of heart failure. More
research is needed to show the full effects of digitalis.
B A C K G R O U N D
Until the past three decades, no full-scale randomized trials of dig-
italis versus placebo were conducted, in part because of concerns
about the use of placebo controls to replace the active agent. How-
ever, several clinical studies have appeared, showing that digitalis
in many instances could be safely withdrawn in participants with
HF (Dall 1970; Fonrose 1974; Gheorghiade 1983; Hull 1977;
Johnston 1979; McHaffie 1978; Starr 1969). At the same time,
studies appeared suggesting that digitalismay have favorable short-
term effects on exercise tolerance, symptoms, and cardiovascular
event rates (Arnold 1980; Dobbs 1977; Firth 1980; Fleg 1991;
Kirsten 1973; O’Rourke 1976; Vogel 1977). Some concern has fo-
cused on possible long-term toxicity from digitalis, as well as other
inotropic agents. The latter was suggested by studies of treatment
with the phosphodiesterase inhibitors milrinone (Packer 1991)
and enoximone (Cowley 1994), as well as other agents such as
the inodilator vesnarinone (Cohn 1998). Digitalis itself was impli-
cated in several nonrandomized trials suggesting that patients with
HF treated with digitalis might show excessive mortality rates, par-
ticularly when the underlying clinical diagnosis was ischemic heart
disease (Bigger 1985; Byington 1985; Moss 1981). Thus conflict-
ing evidence shows that some studies have suggested that digitalis
might be discontinued without adverse effects, others have indi-
cated that beneficial effects might indeed be present, and still oth-
ers have suggested that digitalis might have long-term toxic effects.
Over the past 31 years, informationhas become available that helps
to settle these points. Since 1982, 12 randomized controlled trials
of digitalis in HF participants have been published (Blackwood
1990; Dig captopril 1988; Dig milrinone 1989; Dig xamoterol
1988;DIMT1993; Fleg 1982;Guyatt 1988; Lee 1982; PROVED
1993; Pugh 1989; RADIANCE 1993; Taggart 1983), indicating
that digitalis improves clinical outcomes-a conclusion reached in
a meta-analysis of the first seven of these trials published in 1990
(Jaeschke 1990). In addition, a large randomized controlled trial
has been published showing that digitalis, while improving hos-
pitalization rates, has no significant effect on long-term mortality
(DIG study 1997). The current review updates the 1990 meta-
analysis and provides a summary statement about the current sta-
tus of digitalis in treating HF. Although the utility of digitalis gly-
cosides for controlling heart rate in patients with rapid atrial fib-
rillation is well recognized, the current review is restricted to the
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use of digitalis in patients who are in normal sinus rhythm.
O B J E C T I V E S
To examine the effectiveness of digitalis glycosides in treating HF
in patients with normal sinus rhythm. To examine the effects of
digitalis in patients taking diuretics and angiotensin-converting
enzyme inhibitors; in patients with varying severity and duration
of disease; in patients with prior exposure to digitalis versus no
prior exposure; and in patients with “HF due to systolic dysfunc-
tion” versus “HF with preserved ejection fraction.”
M E T H O D S
Criteria for considering studies for this review
Types of studies
The central feature of this review is a consideration of the 13 ran-
domized controlled trials selected for inclusion, particularly the
data they provide on mortality, hospitalization, and clinical status.
Entry criteria were based on the earlier 1990 study (Jaeschke 1990)
and included only double-blind randomized trials with placebo
controls, a treatment period of seven weeks or longer, and evalu-
ation of each trial for sensibility of entry criteria, method of ran-
domization, completeness of follow-up, and method of handling
withdrawals.
Types of participants
This review includes adult participants of both sexes with HF,
older than 18 years of age, and of any ethnic group. Criteria for
diagnosing HF varied among the studies, but all employed clinical
criteria such as presence of dyspnea, orthopnea, rales, S3 gallop,
neck vein distention, or peripheral edema. In addition, ejection
fraction was measured in some studies. For the purposes of this
review, the presence of an ejection fraction of 0.45 or less was
considered as identifying a subgroup of individuals having “HF
due to systolic dysfunction.” Patients with an ejection fraction
greater than 0.45 were considered to have “HF with preserved
ejection fraction.” Duration of HF and history of prior treatment
with digitalis are noted when stated.
Digitalis is effective in slowing heart rate in patients with atrial
fibrillation, although the effect is a modest one (DAAFTrial 1997;
Jordaens 1997). This agent was formerly thought to be of value in
causing reversion of atrial fibrillation to sinus rhythm, although
the latter theory has been disproved (DAAFTrial 1997; Falk 1987;
Jordaens 1997). The advent of many newer antiarrhythmic agents,
which are also effective in reducing the heart rate in rapid atrial
fibrillation, has somewhat restricted the use of acutely adminis-
tered intravenous or oral digitalis in this condition, although it still
is often used as long-term oral therapy. Because atrial fibrillation
is frequently present in patients with HF, exclusion of this group
reduces the number of trials available for analysis in the current
report. The therapeutic value of digitalis in patients with both HF
and atrial fibrillation is, however, an important clinical issue and
may be considered in a future review.
Types of interventions
The literature search included participants treated orally with any
commonly used digitalis preparation, such as digoxin or digitoxin.
For the purposes of this review, the term “digitalis” is used to refer
to any of these treatments, although in practice, digoxin was the
only agent employed in the 13 included studies. If the information
was available, data are included on the incidence of prior treatment
with digitalis, dosage levels utilized, and serum or plasma levels
achieved. Use of other concurrent cardiac medications, including
diuretics, angiotensin-converting enzyme (ACE) inhibitors, and
beta-blocking agents, is also recorded.
Types of outcome measures
This review focuses on mortality, hospitalization, and clinical sta-
tus in the 13 trials considered in the analysis. When available, data
are also included on New York Heart Association (NYHA) class,
quality of life as measured by various instruments, treadmill or bi-
cycle exercise test or walk test performance, and various measures
of myocardial size or performance.
The quality of data from trials accepted for the review is assessed
by ascertaining the presence of factors such as concealment of ran-
domization, blinding to allocation and outcome assessment, com-
parability at baseline, and losses to follow-up. Sources of hetero-
geneity are identified by analyzing factors such as dose of digoxin,
whether titration to blood level was employed, use of concomitant
ACE inhibitor therapy, and whether the trial was a withdrawal
trial.
Search methods for identification of studies
The searches, originally run in 2008 (Appendix 1) and re-run for
the previous update in April 2011 (Appendix 2), were updated
in May 2013 (Appendix 3). The Cochrane Central Register of
Controlled Trials (CENTRAL; 2013, Issue 4 of 12), MEDLINE
(Ovid) (1946 to May 2013 Week 2), EMBASE (Ovid) (1947 to
2013 Week 20), and Dissertation Abstracts (to February 2013)
were searched. For this update, we also searched PubMed (http://
www.ncbi.nlm.nih.gov/pubmed) on 21May 2013 to identify any
new records not available through MEDLINE.
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Annual meeting abstracts of the American Heart Association, the
American College of Cardiology, and the European Society of
Cardiology were searched from 1996 to March 2013.
The analysis in MEDLINE was restricted to clinical trials for the
period 1966 to 1984. Both clinical trials and reviews from 1985 to
2013 were examined. In addition, reference lists provided by the
pharmaceutical industry (GlaxoSmithKline and Covis Pharma)
were searched.We also searched the clinical study register of Glax-
oSmithKline (http://www.gsk-clinicalstudyregister.com/). Refer-
ence lists of identified studies and reviews were checked.
No language restrictions were applied.
Data collection and analysis
Quantitative information concerning mortality, hospitalization,
and clinical deterioration was obtained directly from the articles.
Each of these endpoints is presented as a separate meta-analysis,
using the algorithms supplied by Review Manager. The meta-
analyses are based on a fixed-effect model, and data are presented
using the Peto odds ratio.
R E S U L T S
Description of studies
Previous searches up toApril 2011 identified a total of 1854 articles
of possible interest. From these, 19 papers were selected for further
examination. Four papers were excluded (see Characteristics of
excluded studies). Thirteen studies, reported in 15 papers, were
included (see Characteristics of included studies and references for
Included studies). Updated searches fromMay 2013 retrieved 383
new records, for a total of 2237 records examined to date. No new
studies were identified.
The 13 studies included a total of 7896 participants. Of these,
7755 contributed to information on mortality, 7262 to informa-
tion on the incidence of hospitalization due to worsening HF dur-
ing the course of the study, and 1096 to information on clinical
status. The 13 trials varied in size, characteristics of participant
populations, duration, drug dosage, ancillary therapy for HF, and
experimental design. The largest trial-the one of longest duration-
is the study of theDigitalis InvestigationGroup (DIG study 1997),
a multicenter parallel trial in which 6800 participants with “HF
due to systolic dysfunction” were randomly assigned to digoxin or
placebo and were followed over a period of three to five years. The
primary endpoint of this study was mortality, but information was
also provided on the incidence of hospitalization. Because of its
size, the DIG study provided 87.7% of the participants included
in the mortality analysis and 93.6% of those included in the hos-
pitalization analysis. The DIG study also provided 98.0% of the
weight to the meta-analysis for mortality and 97.9% of the weight
for hospitalization. However, the DIG study did not provide in-
formation on symptoms; these data were derived from the other
12 studies, all of which included this information.
Of the 13 studies, six had a parallel design with drug treatment
provided to the active group (Blackwood 1990; Dig captopril
1988;Digmilrinone 1989;DIG study 1997;Dig xamoterol 1988;
DIMT 1993), twowere drugwithdrawal studies (PROVED1993;
RADIANCE 1993), and five had a cross-over design (Fleg 1982;
Guyatt 1988; Lee 1982; Pugh 1989; Taggart 1983). Information
derived from withdrawal studies should perhaps be viewed with
circumspection (De Bono 1994) because all participants by defi-
nition were previously treated with digitalis and were able to toler-
ate the agent (RADIANCE 1993). Therefore they may represent
a group that benefits from the use of digitalis, and this could cre-
ate some bias in favor of the drug. In fact, this type of bias could
also be encountered in parallel trials in which digitalis was ini-
tially withdrawn from all participants before randomization (Dig
captopril 1988; DIG study 1997). Nonetheless, for the purposes
of this review, withdrawal study data are lumped together with
data from other groups. Of the 13 studies, eight were multicenter-
six with a parallel design and two with a withdrawal design. Each
of the other five studies, all with a cross-over design, was carried
out at a single institution. Taken together, data on mortality were
derived from eight of the 13 studies, data on hospitalization from
four, and data on clinical outcomes from 12. Thus no single study
provided information on all three endpoints.
With exclusion of the study of the Digitalis Investigation Group
(DIG study 1997), trial duration varied from seven weeks to six
months; therefore much of the information reported is relatively
short-term. The size of these smaller trials ranged from 20 to
213 participants, with larger numbers recruited into themulticen-
ter trials. Although in most instances, study duration was clearly
specified by the protocol, in one study, it varied somewhat (Lee
1982). Participant characteristics included mean or median age
(three studies reported only median age, i.e. Blackwood 1990;
Dig xamoterol 1988; Pugh 1989), which ranged from 58 to 69
years, and with three exceptions (Blackwood 1990; Dig xamoterol
1988; Fleg 1982), all showed a predominance ofmale participants.
All studies but two (Lee 1982; Pugh 1989) provided information
about NYHA functional class, and most of the participants stud-
ied were NYHA Class II or III. Knowledge about severity of ill-
ness is of importance in assessing whether the effects of digitalis
are dependent on this factor, and comments on this were made
in several studies (Guyatt 1988; Lee 1982). On the other hand,
inclusion of less severely ill participants, as may have been the case
in one of the relevant studies (Dig xamoterol 1988), could limit
the value of the study in contributing information on endpoints
such as mortality, which clearly is higher in more advanced degrees
of HF (CONSENSUS 1987).
All of the 13 studies provided information on the use of diuret-
ics, which were being received by most participants in all but one
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trial (Dig xamoterol 1988). Five of the thirteen trials provided in-
formation on ACE inhibitors, and eight on beta-blocking agents.
Seven of the eight studies published before 1990 did not comment
on the use of ACE inhibitors, most likely reflecting the fact that
these agents were not yet widely available, and that the benefits
of treatment with ACE inhibitors (CONSENSUS 1987; SOLVD
1991) had not yet been recognized. More recently, two trials have
provided specific information on the actions of digoxin in the pres-
ence or absence of concurrent administration of ACE inhibitors.
In the trial reported by Uretsky et al, participants taking ACE in-
hibitors were deliberately excluded, and the trial was ended in part
because of growing evidence that treatment with ACE inhibitors
was of value in HF (PROVED 1993). In the trial reported by
Packer et al, participants taking ACE inhibitors were intention-
ally enrolled (RADIANCE 1993). In the large study conducted
by the Digitalis Investigation Group, use of ACE inhibitors was
encouraged, and 94% of participants were receiving this type of
agent (DIG study 1997). However, comparable information is not
available concerning the concurrent use of beta-blocking agents
and digoxin. Of the eight trials in which information about use of
beta-blocking agents was given, these agents were not being taken
at all in five, and rates of administration in the remaining three
trials were low, ranging from 9% to 20% (Fleg 1982; Pugh 1989;
Taggart 1983).
The incidence of prior treatment with digitalis, reported in 10 of
the 13 studies including by definition the two withdrawal studies,
ranged from 46% to 100%. Duration of HF (range 16 months
to 3.3 years) was reported in only three of the 13 studies (Dig
captopril 1988; DIG study 1997; PROVED 1993). The etiol-
ogy of HF, which was well characterized in all but one study
(Dig xamoterol 1988), was predominantly ischemic.However, the
cause was cardiomyopathy in one-third or more of participants in
three series (Lee 1982; PROVED 1993; RADIANCE 1993). The
incidence of valvular disease was generally low, and such cases were
excluded in three series (DIMT 1993; Guyatt 1988; PROVED
1993), whereas in two studies, the incidence was as high as 34%
(Pugh 1989) and 17% (Fleg 1982). Patients with atrial fibrillation
were excluded in all but two studies. One study (Dig xamoterol
1988) included a small number of participants with this arrhyth-
mia (four of 213, or 1.9%), and in another, a single participant
(one of 108, or 0.9%) had atrial fibrillation (DIMT 1993). It may
also be noted that one study, which otherwise might have qualified
for inclusion, was excluded because 13 of the 46 participants in
the study (28.3%) had atrial fibrillation (Dobbs 1977). The mean
or median dose of digoxin employed (one study reported only the
median dose, i.e. PROVED1993) ranged from 0.25 to 0.435 mg/
d in the seven studies that provided this information, and mean
serum or plasma levels ranged from 0.87 to 1.15 mg/mL in the
six studies that provided these data.
Some information is also provided in the study conducted by the
Digitalis InvestigationGroup on the subgroup of participants with
“HF with preserved ejection fraction,” who have an ejection frac-
tion in the normal or low normal range (DIG study 1997). The
cause of HF in this group may relate to restricted diastolic inflow
into the left ventricle. The etiology, treatment, and prognosis for
this group were less well defined than for participants with low
ejection fractionwho display “HFdue to systolic dysfunction.” Al-
though it was thought previously that digitalis might be relatively
contraindicated in “HF with preserved ejection fraction” (Gaasch
1994), this hypothesis was put to the test by random assignment
of an additional 988 participants with HF who had an ejection
fraction greater than 0.45 to treatmentwith digoxin versus placebo
(DIG study 1997).
Risk of bias in included studies
Concealment of randomizationwas employed in all 13 of the stud-
ies included in this review, but blinding of outcome assessment
is commented on in only five studies. Baseline comparability be-
tween control and treatment groups appeared to be achieved in
all eight of the non cross-over studies. Losses to follow-up were
small (less than 2%) in the three studies that provided these data.
Titration to the level of the dose of digoxin was carried out in six
of the trials. These data, plus information presented earlier, sug-
gest that some heterogeneity in clinical characteristics was present
among these trials. However, the Chi2 and I2 values that accom-
pany the meta-analyses (Analysis 1.1, Analysis 1.2, and Analysis
1.3) do not suggest that the degree of statistical heterogeneity was
great.
Effects of interventions
Meta-analyses on mortality, hospitalization, and
clinical deterioration
A meta-analysis of mortality figures for the eight studies that pro-
vided these data clearly showed that treatment with digoxin had
no effect on death rate (Analysis 1.1). This observation is based
almost entirely on findings in the trial conducted by the Digitalis
Investigation Group (DIG study 1997). Although the number of
deaths in the other seven studies was quite small, the results appear
to be in accord with those of the DIG study (Analysis 1.1). Ad-
ditional information is available from the study conducted by the
Digitalis Investigation Group concerning the causes of mortality,
which were assigned by investigators to the categories of “wors-
ening heart failure” and “other cardiac” (DIG study 1997), the
latter possibly including many deaths attributable to arrhythmia.
The group treated with digoxin showed a trend toward a lower
death rate due to “worsening heart failure” (P value 0.06) and a
significant increase in death due to “other cardiac” causes (P value
0.04), although the latter was not a prespecified endpoint of the
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study. These two opposite directional changes tended to counter-
balance one another, so that the overall effect on survival was neu-
tral. However, the changes are consistent with a small beneficial
effect of digoxin in preventing death directly caused by deteriora-
tion in cardiac function, which may have been offset by a small
increase in mortality resulting from arrhythmias, observations of
which are plausible in view of the known pharmacologic and elec-
trophysiologic actions of digitalis. These findings may provide a
basis for future investigations of factors that predispose to “other
cardiac” death, although none are described in the report (DIG
study 1997).
Four studies provided data on hospitalization for worsening HF
(Analysis 1.2). The figure shows that hospitalization for worsen-
ing HF was significantly less common among participants taking
digoxin than in the control group. Point estimates in terms of odds
ratios are shown in the figure, with an overall relative risk reduc-
tion (RRR) of 23.4%. The baseline risk of hospitalization in the
control groups in these four studies, if constant hazard over the
study duration is assumed, ranged from 9.7% to 34.7%, with the
larger figure a function of the much longer duration of the DIG
study. Values for calculated numbers needed to treat for an addi-
tional beneficial outcome (NNTB) ranged from 13 to 17 (Table
1).
Twelve trials presented data on cardiac symptoms (Analysis 1.3).
The figure shows that the clinical status of participants taking
digoxin was better than that of participants assigned to placebo
therapy. Because these 12 smaller trials had many fewer partici-
pants than the DIG study, less than 15% of the entire study popu-
lation was available to contribute to this meta-analysis. Compara-
ble data were not collected in the DIG study, although the group
has published in abstract form a retrospective analysis suggesting
that digoxin does ameliorate symptoms in HF (DIG study 1999).
Point estimates in terms of odds ratios are shown in the figure,
with an overall RRR of 64.5%. The baseline risk of clinical de-
terioration in the control groups in 11 of these studies in which
this calculation could be made, assuming constant hazard over
the study duration, ranged from 3.8% to 46.9%, and calculated
NNTB from 3 to 61 (Table 2).
Other observations
The total series of 13 studies included several other observa-
tions (see Characteristics of included studies). One of these is
the result of treadmill or bicycle exercise testing and of the six-
minute walk test. Unfortunately, these data were not presented
in a consistent manner, and no meta-analysis could be done.
However of the 10 studies using exercise testing (Blackwood
1990; Dig captopril 1988; Dig milrinone 1989; Dig xamoterol
1988; DIMT 1993; Fleg 1982; Guyatt 1988; PROVED 1993;
Pugh 1989; RADIANCE 1993), functional capacity was signifi-
cantly improved by digoxin in four (Dig milrinone 1989; DIMT
1993; PROVED 1993; RADIANCE 1993). Of the three studies
in which a six-minute walk test was carried out (Guyatt 1988;
PROVED 1993; RADIANCE 1993), one showed a beneficial
effect of digoxin (RADIANCE 1993). Of the eight studies in
which assessment of NYHA class or evaluation of a “heart failure
score” was performed (Dig captopril 1988; DIMT 1993; Guyatt
1988; Lee 1982; PROVED1993; Pugh 1989; RADIANCE 1993;
Taggart 1983), the results were significantly better with digoxin
in four (Guyatt 1988; Lee 1982; Pugh 1989; RADIANCE 1993),
whereas no significant change was noted in the other four stud-
ies. Quality of life was assessed in four studies (Blackwood 1990;
Guyatt 1988; PROVED 1993; RADIANCE 1993) and in a sub-
study of the trial conducted by the Digitalis Investigation Group
(Lader 2003), but a significant result favoring digoxin was noted
in only one (RADIANCE 1993). Ejection fraction as a treat-
ment endpoint was measured in five studies (Dig captopril 1988;
Dig milrinone 1989; Lee 1982; PROVED 1993; RADIANCE
1993), and the measurement was significantly better with digoxin
than placebo therapy in four of them (Dig captopril 1988; Dig
milrinone 1989; PROVED 1993; RADIANCE 1993). Cardio-
thoracic ratio was an endpoint in four studies (Fleg 1982; Guyatt
1988; Lee 1982; Taggart 1983), with a result favoring digoxin
noted in two of these studies (Guyatt 1988; Lee 1982). Left
ventricular end-diastolic dimension was measured in six studies
(Fleg 1982; Guyatt 1988; Lee 1982; PROVED 1993; Pugh 1989;
RADIANCE1993), with a result favoring digoxin therapy in three
of them (Fleg 1982; Lee 1982; RADIANCE 1993). In general,
these findings suggest a beneficial effect from digitalis treatment,
although the results were by no means uniform or consistent. One
may conclude that digitalis does have favorable effects, but that
they are not very pronounced and may not be observed in all pa-
tients. This point has been made in several of the publications
included in this review (Dig xamoterol 1988; Fleg 1982; Guyatt
1988; Taggart 1983).
Additional observations were made in the ancillary study con-
ducted by the Digitalis Investigation Group in 988 participants
with “HFwith preserved ejection fraction” (DIG study 1997). The
pathophysiologic mechanism in this group of participants may re-
late to restricted diastolic inflow into the left ventricle. Concern
has been expressed about whether treatment with digoxin is rela-
tively contraindicated, as the agent could reduce ventricular dias-
tolic compliance (Gaasch 1994). However, findings of the study
conducted by the Digitalis Investigation Group do not support
this concept (Ahmed 2006; DIG study 1997), as no difference in
mortality was seen in participants with “HF with preserved ejec-
tion fraction” who received digoxin (N = 492) versus placebo (N
= 496). In addition, a trend toward reduction in the combined
outcome of death or hospitalization due to worsening heart failure
was observed (risk ratio 0.82, 95% confidence interval 0.63 to
1.07).
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D I S C U S S I O N
Use of digitalis in the treatment of HF has been consider-
ably attenuated by the widespread acceptance of ACE inhibitors
(CONSENSUS 1987; SOLVD 1991) and beta-blocking agents
(Carvedilol 1996;CIBIS II 1999;MERIT-HF1999; Packer 2001)
for treating this syndrome. Use of ACE inhibitors and beta-block-
ing agents is based on randomized clinical trials that conclusively
show that both agents decrease mortality. Failure of digoxin to re-
duce mortality suggests that agents with a mortality benefit-ACE
inhibitors and beta-blocking agents-should be offered to patients
in preference to the older drug. However, the present review does
show that digoxin therapy can have beneficial effects, even in pa-
tients already treated with ACE inhibitors, and most participants
in the trials that demonstrated benefits of digoxin for clinical status
were also receiving diuretics. Based on these findings, clinicians
can offer digoxin to patients who remain symptomatic despite
treatment with ACE inhibitors and to those at appreciable risk of
hospitalization, with reasonable expectation of benefit. Whether
these findings generalize to patients receiving beta-blockers is un-
known at the present time, although a retrospective study showed
no benefit of digoxin therapy in a group of predominantly male
participants receiving contemporary therapy that included beta-
blockers (Dhaliwal 2008).
Beta-blocking agents are now, in conjunction with ACE in-
hibitors, the cornerstone of treatment for HF (CIBIS II 1999;
COPERNICUS 2002;MERIT-HF 1999; SENIORS 2005). Any
information yet to be derived in future trials about treatment of
HF with digoxin will be obtained in the setting of concurrent
treatment with ACE inhibitors plus beta-blocking agents. Also
of note are findings that the aldosterone inhibitors spironolac-
tone (RALES 1999) and eplerenone (Zannad 2011) and the an-
giotensin receptor blockers valsartan (Cohn 2001) and candesar-
tan (CHARM 2003) have beneficial long-term effects in HF. All
of these agents appear to be effective in groups of participants
with substantial levels of digoxin usage: 73% in the spironolactone
trial (RALES 1999), 27% in the eplerenone study (Zannad 2011),
67% in the valsartan trial (Cohn 2001), 43% in the candesartan
trial (CHARM 2003), and more than 50% in some beta-blocker
trials (CIBIS II 1999; Packer 2001), with demonstrable continu-
ing effectiveness in participants already receiving digitalis.
Although theDIG study showed no reduction inmortality among
participants receiving digoxin, the overall effect on reduction of
HF hospitalization of 7.9% was substantial (DIG study 1997).
This effect occurred within one month of the start of therapy (
Bourge 2013) andwas sustained (Ahmed 2009). Regarding the use
of digitalis in patients withHF of varying severity, individuals with
impaired cardiac function who have few or no symptoms (NYHA
Class I) and are at low risk for exacerbations or hospitalizations,
as occurred in 25% of participants in one of the trials reported
here (Dig xamoterol 1988), are very unlikely to receive important
benefit fromdigoxin.The bulk of information available for digoxin
therapy pertains to patients whose status is NYHA Class II or III,
and this is the group in which digoxin improves symptoms and
decreases exacerbations. Some evidence suggests that patients with
more advanced symptoms may respond better to digoxin than
those with less severe HF (Adams 1998; DIG study 1997; DIMT
1993; Gheorghiade 2013; Guyatt 1988; Lee 1982). In one study
it was noted that participants with an S3 gallop and a dilated and
poorly functioning ventricle may tend to respond most favorably
to digoxin (Lee 1982). Other investigators have sought to confirm
this observation but with somewhat less striking results (Guyatt
1988).
The issue of dosage of digitalis and its use in various subgroups
has also been explored, with several publications based on ret-
rospective analyses of the large trial carried out by the Digitalis
Investigation Group (DIG study 1997). Such findings must be
interpreted cautiously and need to be confirmed in prospective
studies. Lower doses appear to be associated with beneficial ef-
fects (ACC/AHAGuidelines 2005; Adams 2002; ESCGuidelines
2008; HFSA Guideline 2006), as demonstrated in the large DIG
study, in which the median baseline dosage of digoxin was 0.25
mg/d (DIG study 1997). A post-hoc analysis of the DIG study
suggested that lower doses and serumdigoxin levelswere associated
with reducedmortality and hospitalization in comparisonwith the
placebo group (Ahmed 2009), and another post-hoc analysis of
the results in the DIG study suggested that higher serum digoxin
levelswere associatedwith an increase inmortality (Rathore 2003).
On the other hand, evidence shows that larger doses of digoxin
are associated with improved efficacy (RADIANCE 1993; Slatton
1997). Furthermore, results from two of the trials (PROVED
1993; RADIANCE 1993) suggest that clinical efficacy was inde-
pendent of the digoxin dosage (Adams 2002). In summary, re-
sults indicate that patients may receive comparable benefits from
digoxin dosage regimens that are in current use, although some
caution may be required when higher doses are employed.
With regard to differential effects in men and women, a post-
hoc analysis of the DIG study observed that digoxin therapy was
associated with an increase in mortality in women, but not in
men (Rathore 2002)-an observation supported by a recent clus-
ter analysis of the DIG study data (Ather 2011). The difference
was more pronounced in those with higher serum digoxin levels
(Adams 2005). This gender differentiation is not, however, consis-
tent (Domanski 2005). No evidence suggests that age (Rich 2001)
or duration of HF is important in the decision of who should re-
ceive digoxin, and evidence from yet another DIG study post-hoc
analysis suggests that the drug is effective in low doses and with
low serum digoxin levels in a geriatric population (Ahmed 2007).
No evidence suggests a selective advantage for digoxin therapy in
patients whose HF is of ischemic or cardiomyopathic origin.
Based on yet another post-hoc analysis in a subset of participants
in the DIG study (DIG study 1997), evidence that digoxin im-
proves renal function has been observed (Testani 2011). In addi-
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tion, beneficial effects of digoxin on the combined endpoint of
cardiovascular death and hospitalization for worsening HF in the
DIG study were comparable to those occurring in HF patients
receiving the sinus node If inhibitor ivabradine (Castagno 2012).
These findings are perhaps attributable to the bradycardic action
of ivabradine comparable to heart rate slowing by digoxin result-
ing from its known effects on vagal tone. This observation may
stimulate further studies to determine the importance of heart rate
reduction in treating HF patients.
Although the emphasis in this review is on the beneficial effects
of digitalis, it provides more valid data on effectiveness than on
harm. However, toxic effects of digitalis therapy are well known
and include adverse interactionswith other drugs, electrolytes, and
various disease states, as well as induction of proarrhythmias. In
addressing the issue of postmarketing surveillance, the US Food
and Drug Administration (FDA) archives provide an extensive
list of these adverse effects but are lacking long-term follow-up in
large numbers of patients analogous to the RCT approach used to
evaluate beneficial effects.
Findings in the ancillary study of theDigitalis InvestigationGroup
in patients having “HF with preserved ejection fraction” raise new
questions about this entity (DIG study 1997). Although it is ev-
ident that a substantial fraction of patients with HF may share
this pathophysiology (Jones 2004; Vasan 1999), the etiology, treat-
ment, and prognosis for this group are less well defined than for
patients having “HF due to systolic dysfunction.” Some investiga-
tors have suggested that the prognosis may be more favorable in
patients having “HFwith preserved ejection fraction” than in those
with ”HF due to systolic dysfunction“ (Vasan 1999), as was the
case in the ancillary study (DIG study 1997). Although the DIG
study ancillary trial showed a trend toward better outcomes in the
group receiving digoxin for the combined endpoint of death or
hospitalization due to worsening heart failure (DIG study 1997),
it is still possible that digoxin is not beneficial or may even be
harmful in several conditions in which ”HF with preserved ejec-
tion fraction“ is present. These may include such conditions as
hypertrophic cardiomyopathy and amyloid infiltration of the my-
ocardium (Chew 1975). Four participants in one of the series in-
cluded in this review (Lee 1982) had a diagnosis of hypertrophic
cardiomyopathy, but none of these participants responded posi-
tively to digoxin therapy.
The mechanism of action of digoxin is also of interest. Digi-
talis has multiple effects on cardiac function at the cellular level
(Wasserstrom 2005), but the mechanism by which beneficial ef-
fects on the failing heart are produced is not fully understood. The
traditional view has been that the drug exerts beneficial inotropic
effects on the failing heart, but more recent evidence suggests that
reduction of augmented adrenergic tone and renin-angiotensin
system activation in HF may also play a role (Packer 1992; Packer
1999). Evidence indicates that digoxin treatment of patients with
HF can reduce sympathetic tone (Ferguson 1989; Gheorghiade
1991), as exemplified in one study among the 13 included in this
report that demonstrated a reduction in circulating catecholamine
levels in the digoxin-treated group (DIMT 1993). Digoxin ther-
apy may also inhibit the renin-angiotensin system (Covit 1983)
and augments vagal tone, as evidenced by an increase in heart
rate variability (DIMT 1995) and frequent occurrence of sinus
node slowing (Castagno 2012). These observations may relate to
the question raised earlier regarding the effects of digoxin ther-
apy in patients who are already taking beta-blocking agents be-
cause the latter could abrogate the sympatholytic effects of digoxin
(Hauptman 1999). However, ACE inhibitors also reduce sympa-
thetic tone, yet digoxin is known to be effective in this group of
patients (RADIANCE 1993).
The key question is whether digoxin added to a treatment regimen
that already includes ACE inhibitors and beta-blocking agents,
or some combination of these agents with spironolactone or the
angiotensin receptor blockers valsartan or candesartan, produces
additional gains. The preferable sequence for adding digoxin,
spironolactone, or an angiotensin receptor blocker to established
treatment with ACE inhibitors and beta-blockers remains uncer-
tain at the present time. However currently available data indicate
that spironolactone (RALES 1999), candesartan (CHARM2003),
and eplerenone (Zannad 2011)may reducemortality andmorbid-
ity in patients with HF, and both digoxin (DIG study 1997) and
valsartan (Cohn 2001), as well as candesartan (CHARM 2003),
reduce hospitalization. Digoxin is as least as efficacious as valsar-
tan and candesartan in this respect. Another issue is whether there
are different indications for these agents in NYHA Class IV HF.
Finally, there is the question of whether digoxin truly has a differ-
ent mechanism of action in patients having ”HF due to systolic
dysfunction“ versus ”HF with preserved ejection fraction,“ and
whether this is dependent on the underlying cause of the two syn-
dromes. In patients having ”HF with preserved ejection fraction,“
does digoxin actually have any therapeutic potential?
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of the present meta-analyses further strengthen the
concept that digoxinmay have beneficial effects in treating patients
with HF who remain symptomatic despite therapy with ACE in-
hibitors, diuretics, and possibly beta-blockers. The agent has been
shown to improve clinical status and to reduce hospitalizations.
Although some authors have stated that the agent is of limited
value, and its ultimate role in the current era of improved pharma-
cotherapy for HF remains untested, the agent may still have value
as adjunctive therapy. The significant rise in ”other cardiac” deaths
possibly due to arrhythmias warrants cautious use in patients at
risk for such events.
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Implications for research
Several unanswered questions may ultimately deserve further in-
vestigation. Concerns about dosage and specific indications for
digoxin therapy in different subgroups have led to the sugges-
tion that additional clinical trials in the future may be warranted
(Ahmed 2009; van Veldhuisen 2002). It has also been recom-
mended that studies of the drug be carried out in acute heart fail-
ure syndromes (Gheorghiade 2009). Of considerable interest is
the question whether there is truly a slight decrease in mortality
due to ”worsening heart failure“ and an increase in mortality due
to ”other cardiac“ causes in patients taking digoxin (DIG study
1997), but further studies on the point are lacking.
Despite more than two centuries of use, up-to-date information
about digitalis is still not available in the current era, when several
newer first-line agents have been identified for the treatment of
HF. The DIG study is now 16 years old, and although most of the
study participants were taking ACE inhibitors, definitive informa-
tion about interactions with beta-blockers and with angiotensin
receptor blockers and aldosterone inhibitors is lacking. Perhaps in
the future, studies will be carried out to address these unknowns.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Blackwood 1990
Methods three-mo multicenter parallel trial with third xamoterol arm; endpoints-ET, QOL
Participants 61 pts; *median age 60; 50% male; 94% Class II, 6% Class III; 56% on diuretics; dx-
~67% ischemic
*Note: Figures shown in ”Participants“ section show composite data from all three study
arms, except for number of pts
Interventions dig dosage 0.25 mg/d
Outcomes for dig vs pla, no significant difference in ET, QOL
Notes blind allocation-yes
blinded to outcomes-?
baselines comparable-yes
loss to follow-up-?
dig titrated to level-no
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
Dig captopril 1988
Methods six-mo multicenter parallel trial with third captopril arm; primary endpoint-ET; secondary
endpoints-NYHA class, hospitalization, EF
Participants 196 pts; mean age 58; 83% male; 80% Class II; 87% on diuretics, none on beta-blockers;
mean EF 0.25; mean duration of HF 3.0 yrs; prior dig Rx in 68%; dx-61% ischemic, 31%
cardiomyopathic
Interventions dig dosage of 0.125 to 0.375 mg/d titrated to serum levels of 0.7 to 2.5 ng/mL
Outcomes for dig versus pla, ET +10% & +6% (P value NS), EF +17% & +3% (P < 0.01); NYHA
class improved in 31% of dig versus 22% of pla (P value NS)
Notes blind allocation-yes
blinded to outcomes-?
baselines comparable-yes
loss to follow-up-?
dig titrated to level-yes
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Dig captopril 1988 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
Dig milrinone 1989
Methods 12-wk multicenter parallel trial with third milrinone arm & fourth dig + milrinone arm;
endpoints-ET, EF
Participants 111 pts; mean age 60; 76% male; 32% Class II, 66% Class III; 100% on diuretics, none
on beta-blockers; mean EF 0.25; dx-53% ischemic, 32% idiopathic
Interventions dig dosage 0.125 to 0.5 mg/d
Outcomes ET +14% for dig (P < 0.03 compared with pla); EF +6.7% for dig, -8.2% for pla (P < 0.
01)
Notes blind allocation-yes
blinded to outcomes-yes
baselines comparable-yes
loss to follow-up-?
dig titrated to level-no
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
DIG study 1997
Methods Three- to five-yr (mean follow-up 37 mo) multicenter parallel trial; primary endpoint-
mortality; secondary endpoint-hospitalization for HF
Participants 6800 pts with EF ≤ 0.45 in main trial; mean age 63; 88% male; 54% Class II, 31% Class
III; 82% on diuretics, 94% on ACEI; EF 0.29 & 0.28 (dig & pla); median duration of HF
17 & 16 mo (dig & pla); prior dig Rx in 44%; dx-71% ischemic, 15% idiopathic. Note:
ancillary trial carried out in 988 additional pts with EF > 0.45
Interventions dig dosage at investigators’ discretion; median baseline dosage in main trial of 0.25 mg/d
Outcomes main trial mortality, dig versus pla: overall 34.8%&35.1% (P value 0.80), from ”worsening
heart failure“ 11.6% & 13.2% (P value 0.06), from ”other cardiac“ 15.0% & 13.0% (P
value 0.04); main trial hospitalization, dig versus pla: 26.8%&34.7% (P < 0.001); ancillary
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DIG study 1997 (Continued)
trial mortality 23.4% in both groups
Notes blind allocation-yes
blinded to outcomes-?
baselines comparable-yes
main trial loss to follow-up-1.4%
dig titrated to level-no
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
Dig xamoterol 1988
Methods Three-mo multicenter parallel trial with third xamoterol arm; endpoints-EX, symptoms,
signs
Participants 213 pts; median age 62; 38% male; 25% Class I, 62% Class II, 13% Class III; 22% on
diuretics, none on ACEI or beta-blockers; prior dig Rx in 46%; dx-unspecified in 76% of
pts
Interventions dig dosage 0.25 mg/d, mean plasma dig level 0.87 ng/mL
Outcomes for dig versus pla, no significant difference in EX; symptoms: Likert but not VAS improved
by dig; signs: edema & rales improved by dig, but not JVP or hepatomegaly
Notes blind allocation-yes
blinded to outcomes-?
baselines comparable-yes
loss to follow-up-?
dig titrated to level-no
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
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DIMT 1993
Methods Six-mo multicenter parallel trial with third ibopamine arm; primary endpoint-EX; sec-
ondary endpoints-”heart failure score,“ change in plasma norepinephrine
Participants 108 pts; mean age 61; 86% male; 80% Class II, 20% Class III; 100% on diuretics, none
on ACEI or beta-blockers; dx-69% ischemic, 31% idiopathic; valvular disease excluded
Interventions dig dosage 0.25 mg/d, mean plasma level 0.94 ng/mL
Outcomes for dig versus pla, EX +1.6% & -5.8% (P value 0.008); no significant difference in ”heart
failure score;“ plasma norepinephrine values changed
by -106 pg/mL for dig & +62 pg/mL for pla (P < 0.001)
Notes blind allocation-yes
blinded to outcomes-?
baselines comparable-yes
loss to follow-up-?
dig titrated to level-no
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
Fleg 1982
Methods Three-mo cross-over trial; endpoints-ET, CT ratio, LVED, FS, Vcf
Participants 30 pts; mean age 69; 47% male; 53% Class II, 43% Class III; 77% on diuretics, 13% on
beta-blockers; prior dig Rx in 87%; dx-63% ischemic, 17% valvular
Interventions dig dosage titrated to serum dig level of 1.0 to 2.0 ng/mL
Outcomes for dig versus pla, no difference in ET, CT ratio, FS; LVED 55.8 & 57.6 mm (P < 0.001),
Vcf 0.90 & 0.82 circ/s (P < 0.05)
Notes blind allocation-yes
blinded to outcomes-?
baselines comparable-NA
loss to follow-up-?
dig titrated to level-yes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
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Guyatt 1988
Methods Seven-wk cross-over trial; endpoints-”heart failure score,“ six-minute walk test, CT ratio,
QOL, LVED, FS, EX
Participants 20 pts; mean age 63; 90% male; 50% Class II, 40% Class III; 90% on diuretics; prior dig
Rx in 85%; dx-85% ischemic; valvular disease excluded
Interventions dig dosage titrated to serum level of 1.54 to 2.56 nmol/L (1.2 to 2.0 ng/mL), mean dig
dosage 0.391 mg/d
Outcomes for dig versus pla, ”heart failure score“ 2.3 & 4.4 (P value 0.001), six-minute walk test 411
& 392 m (P value 0.055), CT ratio 0.53 & 0.58 (P value 0.04), FS 21% & 17% (P value
0.04); no significant difference in QOL profile, LVED, EX
Notes blind allocation-yes
blinded to outcomes-yes
baselines comparable-NA
loss to follow-up-?
dig titrated to level-yes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
Lee 1982
Methods cross-over trial, mean treatment duration 53 days for both dig & pla; endpoints-”heart
failure score,“ CT ratio, LVED, EF
Participants 25 pts; mean age 61; 72% male; 88% on diuretics; mean EF 0.29; prior dig Rx in 96%;
dx-60% ischemic, 24% cardiomyopathic, 16% hypertrophic cardiomyopathy
Interventions dig dosage titrated to mean serum level of 1.15 ng/mL, mean dig dosage 0.435 mg/d
Outcomes for dig versus pla, ”heart failure score“ 2.0 & 3.6 (P < 0.05), CT ratio 0.51 & 0.53 (P value
0.00027), LVED 31 & 33 mm/sq m (P value 0.0026), EF 0.30 & 0.29 (P value NS)
Notes blind allocation-yes
blinded to outcomes-yes
baselines comparable-NA
loss to follow-up-?
dig titrated to level-yes
Risk of bias
Bias Authors’ judgement Support for judgement
18Digitalis for treatment of heart failure in patients in sinus rhythm (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lee 1982 (Continued)
Allocation concealment (selection bias) Low risk A-Adequate
PROVED 1993
Methods 12-wk multicenter withdrawal trial; primary endpoint-ET, six-minute walk test; secondary
endpoints-QOL, ”heart failure score,“ global evaluation of progress, LVED, EF
Participants 88 pts; mean age 64; 85% male; 83% Class II or III; 100% on diuretics, none on ACEI
or beta-blockers; mean EF 0.28; mean duration of HF 3.3 yrs; prior dig Rx in 100%; dx-
64% ischemic, 36% cardiomyopathic; valvular disease excluded
Interventions dig dosage titrated to mean serum level of 1.2 ng/mL, median digoxin dosage 0.375 mg/d
Outcomes for dig versus pla,medianET change +1%&-18% (P value 0.003); no significant difference
in six-minute walk test, QOL profile, ”heart failure score,“ global evaluation of progress,
LVED; EF +7% for dig & -10% for pla (P value 0.016)
Notes blind allocation-yes
blinded to outcomes-yes
baselines comparable-yes
loss to follow-up-1.1%
dig titrated to level-yes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
Pugh 1989
Methods Eight-wk cross-over trial; endpoints-clinical score, systolic time intervals (LVET, PEP, PEP/
LVET, LVED, FS, Vcf, ET)
Participants 44 pts; median age 62; 73% male; 75% on diuretics, 20% on beta-blockers; prior dig Rx
in 100%; dx-61% ischemic, 34% valvular
Interventions dig dosage was ”the patient’s usual dose“
Outcomes for dig versus pla, worsened clinical score in 11% versus 25% of pts (P < 0.04); borderline
decrease in PEP (P ≤ 0.08), no significant differences in LVED, PEP/LVET, FS, Vcf, ET
Notes blind allocation-yes
blinded to outcomes-?
baselines comparable-NA
loss to follow-up-?
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Pugh 1989 (Continued)
dig titrated to level-no
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
RADIANCE 1993
Methods Three-mo multicenter withdrawal trial; primary endpoints-clinical deterioration, ET, six-
minute walk test; secondary endpoints-symptoms, QOL, functional class, LVED, EF
Participants 178 pts; mean age 60; 76%male; 73% Class II, 27% Class III; 100% on diuretics & ACEI;
mean EF 0.27; prior dig Rx in 100%; dx-60% ischemic, 38% cardiomyopathic
Interventions dig dosage titrated to mean serum level of 1.2 ng/mL, mean dig dosage 0.38 mg/d
Outcomes for dig versus pla, ET 43 seconds greater (P value 0.033), six-minute walk test 41 m further
(P value 0.01), better self-assessed symptoms (P value 0.007) & QOL profile (P value 0.
04), less deterioration in class (10% vs 27%, P value 0.019); LVED -1.4% versus +3.0%
(P value 0.04), EF -3.7% versus -13.3% (P value 0.001)
Notes blind allocation-yes
blinded to outcomes-yes
baselines comparable-yes
loss to follow-up-1.7%
dig titrated to level-yes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
Taggart 1983
Methods Three-mo cross-over trial; endpoints-”heart failure score,“ CT ratio, systolic time intervals
(LVET, PEP, PEP/LVET)
Participants 22 participants; mean age 65; 64% male; 82% Class II; 95% on diuretics, 9% on beta-
blockers; prior dig Rx in 100%; dx-77% ischemic, 9% valvular
Interventions mean plasma dig level 1.2 ng/mL
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Taggart 1983 (Continued)
Outcomes for dig versus pla, no significant difference in ”heart failure score,“ CT ratio; LVET 388 &
403 msec (P < 0.001), PEP 128 & 138 msec (P < 0.001), PEP/LVET 0.39 & 0.41 (P < 0.
02)
Notes blind allocation-yes
blinded to outcomes-?
baselines comparable-NA
loss to follow-up-?
dig titrated to level-no
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A-Adequate
Abbreviations:
ET = treadmill exercise time.
class = NYHA functional class.
EF = ejection fraction.
pts = participants.
HF = heart failure.
dig = digoxin.
Rx = treatment.
dx = diagnosis.
pla = placebo.
ACEI = angiotensin-converting enzyme inhibitors.
EX = bicycle exercise.
VAS = visual analogue scale.
JVP = jugular venous pulse.
CT ratio = cardiothoracic ratio.
QOL = quality of life.
LVED = left ventricular end-diastolic dimension.
FS = fiber-shortening fraction.
Vcf = circumferential fiber shortening velocity.
LVET = left ventricular ejection time.
PEP = pre-ejection period.
mo = month.
wk = week.
yr = year.
Note: For studies of dig versus pla with additional arms, all data shown are for the dig and pla groups only.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dobbs 1977 Atrial fibrillation in 28.3% of participants
Fleg 1991 Ten participants, studied using cross-over design over two four-week periods
Just 1993 Study in 133 participants directed at individuals ”without significantly reduced ejection fraction at rest“
Kostis 1994 Seven participants randomly assigned to digitalis and six to placebo
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D A T A A N D A N A L Y S E S
Comparison 1. Digitalis versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Figure 1-Mortality 8 7755 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.89, 1.09]
2 Figure 2-Hospitalization 4 7262 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.61, 0.75]
3 Figure 3-Clinical deterioration 12 1234 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.31 [0.21, 0.43]
A D D I T I O N A L T A B L E S
Table 1. Hospitalization
Study Baseline risk Odds ratio NNTB Study duration Comment
Dig captopril 1988 11.0% 0.31 13 six months
DIG study 1997 34.7% 0.69 13 mean 37 months Note NNTB similar despite longer study dura-
tion
PROVED 1993 13.0% 0.53 17 three months
RADIANCE 1993 9.7% 0.28 14 three months
Table 2. Clinical deterioration
Study Baseline risk Odds ratio NNTB Study duration
Blackwood 1990 6.7% 0.13 15 three months
Dig captopril 1988 15.0% 0.29 10 six months
Dig milrinone 1989 46.9% 0.21 4 12 weeks
Dig xamoterol 1988 5.5% 0.69 61 three months
DIMT 1993 3.8% 0.13 27 six months
Guyatt 1988 35.0% 0.09 3 seven weeks
Lee 1982 36.0% 0.57 9 mean 53 days
PROVED 1993 19.6% 0.57 14 12 weeks
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Table 2. Clinical deterioration (Continued)
Pugh 1989 25.0% 0.40 8 eight weeks
RADIANCE 1993 24.7% 0.21 5 three months
Taggart 1983 19.0% 0.49 12 three months
WH A T ’ S N E W
Last assessed as up-to-date: 21 May 2013.
Date Event Description
30 July 2013 New citation required but conclusions have not changed No new studies were identified by the updated search.
Minor changes were made to theDiscussion. Conclusions
have not changed
30 July 2013 New search has been performed Searches were re-run in May 2013.
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 1, 2001
Date Event Description
13 April 2011 New search has been performed The search was re-run in April 2011. No new studies
were identified. Minor changes were made to the Dis-
cussion. Conclusions not changed
17 December 2008 New search has been performed The search was updated to November 2008. No new
studies were identified. Minor changes were made to
discussion. Conclusions not changed
7 September 2008 Amended Converted to new review format.
3 October 2006 Amended The searchwas updated to August 2006. No new stud-
ies were found. Minor changes have been made to the
discussion to take account of newly identified refer-
ences
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(Continued)
1 February 2004 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
All review authors participated in preparation of the final review by preparing critiques of the protocol and of various drafts of the
review. Statistical input was also provided (GHG and RJ).
D E C L A R A T I O N S O F I N T E R E S T
None.
S O U R C E S O F S U P P O R T
Internal sources
• University of Washington, USA.
• College of Medicine, University of the Philippines, Philippines.
• McMaster University, Canada.
• University of Glasgow, Western Infirmary Glasgow, UK.
External sources
• University of Rochester, USA.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Heart Rate; Cardiotonic Agents [∗ therapeutic use]; Cross-Over Studies; DigitalisGlycosides [∗therapeutic use]; Double-BlindMethod;
Heart Failure [∗drug therapy; mortality; physiopathology]; Hospitalization; Randomized Controlled Trials as Topic
MeSH check words
Humans
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